| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,500 | ₹2.5 0% | 2500% |
| - | - | 4,600 | ₹2.6 0% | 00% |
| - | - | 4,800 | ₹4.75 0% | 2,6250% |
| - | - | 4,900 | ₹9.25 0% | 1250% |
| - | - | 4,950 | ₹8.8 0% | 8750% |
| 1250% | ₹435 0% | 5,000 | ₹7.7 21.25% | 15,875-0.78% |
| - | - | 5,050 | ₹11.7 0% | 5000% |
| - | - | 5,100 | ₹9.6 -26.15% | 4,75052% |
| - | - | 5,150 | ₹14.95 0.67% | 1,375120% |
| 6250% | ₹346.85 0% | 5,200 | ₹17.05 -12.33% | 16,2501.56% |
| 625400% | ₹252.8 -12.31% | 5,250 | ₹29.8 0% | 5,5000% |
| 1,6250% | ₹225 0% | 5,300 | ₹30 -7.12% | 16,125-0.76% |
| 1,6250% | ₹193.85 -7.69% | 5,350 | ₹39.35 -29.73% | 2,375-5% |
| 10,3750% | ₹140 -15.35% | 5,400 | ₹51.1 -14.26% | 20,2506.57% |
| 4,625-45.58% | ₹129.45 -4.39% | 5,450 | ₹68.8 -7.58% | 9,12517.74% |
| 38,1250.66% | ₹102 -4.89% | 5,500 | ₹91 -5.15% | 21,1250% |
| 7,2501.75% | ₹78 -9.3% | 5,550 | ₹126.8 -7.91% | 1,750-30% |
| 93,75019.23% | ₹56.15 -9.43% | 5,600 | ₹173.35 2.93% | 16,2500% |
| 15,875115.25% | ₹43.7 -2.12% | 5,650 | ₹198.35 0% | 5000% |
| 18,2501.38% | ₹32.75 -11.24% | 5,700 | ₹232.65 -7.95% | 87540% |
| 3,0000% | ₹31 0% | 5,750 | ₹287.55 0% | 8750% |
| 6,50036.84% | ₹14.8 -26% | 5,800 | ₹337.95 0% | 2500% |
| 3,7500% | ₹18.6 0% | 5,850 | ₹349.05 -0.01% | 5000% |
| 12,5001.01% | ₹9.2 -12.79% | 5,900 | ₹347.65 0% | 3750% |
| 1250% | ₹14.45 0% | 5,950 | - | - |
| 33,375-4.64% | ₹5.55 -17.77% | 6,000 | - | - |
| 2500% | ₹8 0% | 6,050 | - | - |
| 2,7500% | ₹4.45 0% | 6,100 | - | - |
| 1250% | ₹10.65 0% | 6,200 | - | - |
| 1,3750% | ₹2 0% | 6,300 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
